A pivotal Phase 3 study of Chikungunya Virus Vaccine Candidate (VLA1553-221) in children.
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs VLA 1553 (Primary)
- Indications Chikungunya virus infections
- Focus Adverse reactions; Registrational
- 03 Feb 2025 New trial record
- 22 Jan 2025 According to a Valneva media release, Company expects to initiate a pivotal Phase 3 study in children in the fourth quarter of 2025.